Obesity has reached epidemic proportions and is associated with widespread health problems.
Chronic high-caloric intake and lack of exercise result in the storage of excess energy as lipid in body fat depots. The increases in body fat then trigger metabolic and inflammatory responses that lead to insulin resistance, type 2 diabetes, cardiovascular disease and increased risk of cancer.
Although changes in lifestyle are a first-line treatment option, most patients require additional therapeutic intervention.
DDB studies target G protein-coupled receptors as well as cytokine receptors, and focus on three main avenues for therapy of obesity and diabetes:
- to modulate adipocyte metabolism
- to activate glucose disposal in skeletal muscle
- to enhance and preserve the release of insulin from pancreatic islets
|Analytical Neuropharmacology||Cellular & Molecular Metabolism|
|Dr Celine Valant||Prof Arthur Christopoulos||Prof Mark Febbraio|
|Endocrine & Neuropharmacology||Metabolic GPCR Biology|
|Dr Katie Leach||Dr Karen Gregory||Prof Patrick Sexton||A/Prof Denise Wootten|
|Molecular & Translational Drug Discovery||Receptor Transducer Coupling|
|Dr Chris Langmead||Dr Sebastian Furness|